Assessment of Systemic Inflammatory Response and Nutritional Markers in Patients With Trastuzumab-treated Unresectable Advanced Gastric Cancer

Conclusion: An NLR ≥2.8 is a predictor of poorer prognosis in patients receiving systemic treatment with trastuzumab and chemotherapy for unresectable advanced or recurrent gastric cancer.

Source: In Vivo - August 30, 2020 Category: Research Authors: NAMIKAWA, T., MAEDA, M., YOKOTA, K., TANIOKA, N., FUKUDOME, I., IWABU, J., MUNEKAGE, M., UEMURA, S., MAEDA, H., KITAGAWA, H., KOBAYASHI, M., HANAZAKI, K. Tags: Clinical Studies Source Type: research